Literature DB >> 28288066

Is It Time to Reconsider Postoperative Epidural Analgesia in Patients Undergoing Elective Ventral Hernia Repair?: An AHSQC Analysis.

Ajita S Prabhu1, David M Krpata1, Arielle Perez1, Sharon Phillips2, Li-Ching Huang2, Ivy N Haskins1, Steven Rosenblatt1, Benjamin K Poulose3, Michael J Rosen1.   

Abstract

OBJECTIVE: We aimed to evaluate the association of epidural analgesia (EA) with hospital length of stay (LOS), wound morbidity, postoperative complications, and patient-reported outcomes in patients undergoing ventral hernia repair (VHR).
BACKGROUND: EA has been shown to reduce LOS in certain surgical populations. The LOS benefit in VHR is unclear.
METHODS: Patients having VHR performed in the Americas Hernia Society Quality Collaborative (AHSQC) were separated into 2 comparable groups matched on several confounding factors using a propensity score algorithm: one group received postoperative EA, and the other did not. The groups were then evaluated for hospital LOS, 30-day wound morbidity, other complications, and 30-day patient-reported outcomes using pain and hernia-specific quality-of-life instruments.
RESULTS: A 1:1 match was achieved and the final analysis included 763 patients receiving EA and 763 not receiving EA. The EA group had an increased LOS (5.49 vs 4.90 days; P < 0.05). The rate of wound events was similar between the groups. There was an increased risk of having any postoperative complication associated with having EA (26% vs 21%; P < 0.05). Pain intensity-scaled scores were significantly higher (worse) in the EA group versus the non-EA group (47.6 vs 44.0; P = 0.04).
CONCLUSIONS: The LOS benefit of EA noted for other operations may not apply to patients undergoing VHR. Further study is necessary to determine the beneficial role of invasive pain management procedures in this group of patients with an extremely common disease state.

Entities:  

Mesh:

Year:  2018        PMID: 28288066     DOI: 10.1097/SLA.0000000000002214

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

1.  Perioperative factors associated with pain following open ventral hernia repair.

Authors:  Walker Ueland; Margaret A Plymale; Daniel L Davenport; John Scott Roth
Journal:  Surg Endosc       Date:  2019-02-25       Impact factor: 4.584

Review 2.  Enhanced recovery after surgical repair of incisional hernias.

Authors:  K Slim; D Standaert
Journal:  Hernia       Date:  2019-06-08       Impact factor: 4.739

3.  Causes of prolonged hospitalization after open incisional hernia repair: an observational single-center retrospective study of a prospective database.

Authors:  D M Skovgaards; H M H Diab; H G Midtgaard; L N Jørgensen; K K Jensen
Journal:  Hernia       Date:  2021-01-05       Impact factor: 4.739

4.  Effect of Multimodal Analgesia on Opioid Use After Open Ventral Hernia Repair.

Authors:  Jeremy A Warren; Caroline Stoddard; Ahan L Hunter; Anthony J Horton; Carlyn Atwood; Joseph A Ewing; Steven Pusker; Vito A Cancellaro; Kevin B Walker; William S Cobb; Alfredo M Carbonell; Robert R Morgan
Journal:  J Gastrointest Surg       Date:  2017-08-14       Impact factor: 3.452

5.  Direct visualization transversus abdominis plane blocks offer superior pain control compared to ultrasound guided blocks following open posterior component separation hernia repairs.

Authors:  J A Doble; J S Winder; S R Witte; E M Pauli
Journal:  Hernia       Date:  2018-05-02       Impact factor: 4.739

6.  Epidural Analgesia in Ventral Hernia Repair: An Analysis of 30-day Outcomes.

Authors:  Mark R Jones; Ethan Y Brovman; Amy E Wagenaar; Samuel P Ang; Edward E Whang; Alan D Kaye; Richard D Urman
Journal:  Psychopharmacol Bull       Date:  2020-10-15

7.  Comparative effectiveness of surgeon-performed transversus abdominis plane blocks and epidural catheters following open hernia repair with transversus abdominis release.

Authors:  D J Morrell; J A Doble; B S Hendriksen; C M Horne; C S Hollenbeak; E M Pauli
Journal:  Hernia       Date:  2021-07-28       Impact factor: 4.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.